Why the study?
Is argatroban a safe and effective anticoagulant for off-pump coronary artery bypass in patients with heparin-induced thrombocytopenia?
Is argatroban a safe and effective anticoagulant for off-pump coronary artery bypass in patients with heparin-induced thrombocytopenia?
Argatroban can be safely used as an alternative anticoagulant during off-pump coronary artery bypass in patients with heparin-induced thrombocytopenia.
May support argatroban feasibility in HIT for off-pump CABG; hypothesis-generating and should not yet change practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ushijima et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: